Purinostat
Purinostat is a selective inhibitor of HDAC I/IIb with anti-leukemic activity. Purinostat mesylate , the mesylate salt of Purinostat, inhibits the survival of Ph+ leukemic cells and CD34+ leukemic cells derived from CML patients. Purinostat mesylate targets HDAC I/IIb to inhibit several important factors for leukemic stem cell (LSC) survival, including c-Myc, β-Catenin, E2f, Ezh2, Alox5, and mTOR. Purinostat mesylate increases glutamate metabolism in LSC by increasing GLS1[1].
Product Specifications
CAS Number
1929583-17-4
UNSPSC
12352005
Target
HDAC
Related Pathways
Cell Cycle/DNA Damage; Epigenetics
Field of Research
Cancer
Purity
98.04
Smiles
O=C(C1=CN=C(N(CC2=NC3=C(N4CCOCC4)N=C(C5=CC=C(N)C=C5)N=C3N2C)C)N=C1)NO
Molecular Formula
C23H26N10O3
Molecular Weight
490.52
References & Citations
[1]Qiu Q, et al. HDAC I/IIb selective inhibitor Purinostat Mesylate combined with GLS1 inhibition effectively eliminates CML stem cells. Bioact Mater. 2022 Sep 18;21:483-498.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
HDAC1; HDAC2
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
LY418817 100 µg
Transglutaminase 4 (TGM4) (NM_003241) Human Over-expression Lysate
Sign In for Pricing
View Details 